Literature DB >> 29696308

Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice.

Hussein Sultan1, Juan Wu1, Takumi Kumai2, Andres M Salazar3, Esteban Celis4.   

Abstract

Cytotoxic T lymphocytes (CTLs) are effective components of the immune system capable of destroying tumor cells. Generation of CTLs using peptide vaccines is a practical approach to treat cancer. We have previously described a peptide vaccination strategy that generates vast numbers of endogenous tumor-reactive CTLs after two sequential immunizations (prime-boost) using poly-ICLC adjuvant, which stimulates endosomal toll-like receptor 3 (TLR3) and cytoplasmic melanoma differentiation antigen 5 (MDA5). Dendritic cells (DCs) play an important role not only in antigen presentation but are critical in generating costimulatory cytokines that promote CTL expansion. Poly-ICLC was shown to be more effective than poly-IC in generating type-I interferon (IFN-I) in various DC subsets, through its enhanced ability to escape the endosomal compartment and stimulate MDA5. In our system, IFN-I did not directly function as a T cell costimulatory cytokine, but enhanced CTL expansion through the induction of IL15. With palmitoylated peptide vaccines, CD8α+ DCs were essential for peptide crosspresentation. For vaccine boosts, non-professional antigen-presenting cells were able to present minimal epitope peptides, but DCs were still required for CTL expansions through the production of IFN-I mediated by poly-ICLC. Overall, these results clarify the roles of DCs, TLR3, MDA5, IFN-I and IL15 in the generation of vast and effective antitumor CTL responses using peptide and poly-IC vaccines.

Entities:  

Keywords:  Dendritic cells; Interleukin-15; MDA5; Peptide vaccines; Poly-IC; Type-I interferon

Mesh:

Substances:

Year:  2018        PMID: 29696308      PMCID: PMC6585404          DOI: 10.1007/s00262-018-2164-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  47 in total

1.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens.

Authors:  Steffen Jung; Derya Unutmaz; Phillip Wong; Gen-Ichiro Sano; Kenia De los Santos; Tim Sparwasser; Shengji Wu; Sri Vuthoori; Kyung Ko; Fidel Zavala; Eric G Pamer; Dan R Littman; Richard A Lang
Journal:  Immunity       Date:  2002-08       Impact factor: 31.745

2.  IL-15 promotes the survival of naive and memory phenotype CD8+ T cells.

Authors:  Marion Berard; Katja Brandt; Silvia Bulfone-Paus; David F Tough
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

Review 3.  Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens.

Authors:  William R Heath; Gabrielle T Belz; Georg M N Behrens; Christopher M Smith; Simon P Forehan; Ian A Parish; Gayle M Davey; Nicholas S Wilson; Francis R Carbone; Jose A Villadangos
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

Review 4.  Plasmacytoid dendritic cells: linking innate and adaptive immunity.

Authors:  Kelli McKenna; Anne-Sophie Beignon; Nina Bhardwaj
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation.

Authors:  F Mattei; G Schiavoni; F Belardelli; D F Tough
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

Review 6.  Design and development of polymers for gene delivery.

Authors:  Daniel W Pack; Allan S Hoffman; Suzie Pun; Patrick S Stayton
Journal:  Nat Rev Drug Discov       Date:  2005-07       Impact factor: 84.694

7.  CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.

Authors:  Ilia N Buhtoiarov; Hillary Lum; Gideon Berke; Donna M Paulnock; Paul M Sondel; Alexander L Rakhmilevich
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

8.  Polyinosinic-polycytidylic acid-mediated stimulation of human gammadelta T cells via CD11c dendritic cell-derived type I interferons.

Authors:  Volker Kunzmann; Eva Kretzschmar; Thomas Herrmann; Martin Wilhelm
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

9.  Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes.

Authors:  N D Sonawane; Francis C Szoka; A S Verkman
Journal:  J Biol Chem       Date:  2003-08-27       Impact factor: 5.157

10.  CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.

Authors:  J M den Haan; S M Lehar; M J Bevan
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

View more
  10 in total

1.  Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.

Authors:  Anna Pavlick; Ana B Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A Ott; Thomas U Marron; Rose Marie Holman; John Mandeli; Andres M Salazar; Christopher B McClain; Gustavo Gimenez; Sreekumar Balan; Sacha Gnjatic; Rachel Lubong Sabado; Nina Bhardwaj
Journal:  Cancer Immunol Res       Date:  2019-11-07       Impact factor: 11.151

2.  Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.

Authors:  Michael Brown
Journal:  Cancer Treat Res       Date:  2022

3.  A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA.

Authors:  Carcia S Carson; Kyle W Becker; Kyle M Garland; Hayden M Pagendarm; Payton T Stone; Karan Arora; Lihong Wang-Bishop; Jessalyn J Baljon; Lorena D Cruz; Sebastian Joyce; John T Wilson
Journal:  J Control Release       Date:  2022-03-15       Impact factor: 11.467

4.  The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice.

Authors:  Hussein Sultan; Takumi Kumai; Toshihiro Nagato; Juan Wu; Andres M Salazar; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2019-01-02       Impact factor: 6.968

Review 5.  Emerging role of RNA sensors in tumor microenvironment and immunotherapy.

Authors:  Rui Yang; Sihui Yu; Tianhan Xu; Jiawen Zhang; Sufang Wu
Journal:  J Hematol Oncol       Date:  2022-04-12       Impact factor: 17.388

6.  Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein.

Authors:  Julia T Castro; Patrick Azevedo; Marcílio J Fumagalli; Natalia S Hojo-Souza; Natalia Salazar; Gregório G Almeida; Livia I Oliveira; Lídia Faustino; Lis R Antonelli; Tomas G Marçal; Marconi Augusto; Bruno Valiate; Alex Fiorini; Bruna Rattis; Simone G Ramos; Mariela Piccin; Osvaldo Campos Nonato; Luciana Benevides; Rubens Magalhães; Bruno Cassaro; Gabriela Burle; Daniel Doro; Jorge Kalil; Edson Durigon; Andrés Salazar; Otávia Caballero; Helton Santiago; Alexandre Machado; João S Silva; Flávio da Fonseca; Ana Paula Fernandes; Santuza R Teixeira; Ricardo T Gazzinelli
Journal:  Nat Commun       Date:  2022-08-17       Impact factor: 17.694

7.  Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration.

Authors:  Hussein Sultan; Juan Wu; Valentyna I Fesenkova; Aaron E Fan; Diane Addis; Andres M Salazar; Esteban Celis
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

8.  Intratumoral (Poly-ICLC) Therapy for Dogs with Advanced Cancers: First Report on Clinical Effectiveness, Quality of Life, and Adverse Events.

Authors:  Alessandra Rinah Nogueira Voges; Rodrigo Ubukata; Karina Velloso Braga Yazbek; Otávia Luisa Caballero; Andres Mario Salazar; Cristina de Oliveira Massoco; Maria Lucia Zaidan Dagli
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

Review 9.  Antitumor Peptide-Based Vaccine in the Limelight.

Authors:  Takumi Kumai; Hidekiyo Yamaki; Michihisa Kono; Ryusuke Hayashi; Risa Wakisaka; Hiroki Komatsuda
Journal:  Vaccines (Basel)       Date:  2022-01-03

Review 10.  A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy.

Authors:  An Wouters; Evelien L J M Smits; Jorrit De Waele; Tias Verhezen; Sanne van der Heijden; Zwi N Berneman; Marc Peeters; Filip Lardon
Journal:  J Exp Clin Cancer Res       Date:  2021-06-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.